Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
about
Therapeutic modalities for patients with lower-risk myelodysplastic syndromes: current options and future directions.Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis.Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes.
P2860
Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
@en
Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
@nl
type
label
Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
@en
Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
@nl
prefLabel
Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
@en
Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
@nl
P2860
P1476
Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
@en
P2093
P2860
P304
P356
10.1517/14712591003709713
P407
P577
2010-04-01T00:00:00Z